Jaguar Health, Inc. (JAGX) Stock Price

JAGXStock

$0.92−98.55%52W

Market Cap$4.78M

P/E—

PEG Ratio—

Div yield—

Beta-0.17

JAGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-107.04%

Price vs S&P 500 (4W)-8.49%

VGM Score57.17

Book Value / Share (Quarterly)$53.42

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.26%

Cash Flow / Share (Quarterly)$-20.38

Price vs S&P 500 (YTD)-109.16%

Gross Margin (TTM)85.06%

Net Profit Margin (TTM)-115.39%

EPS (TTM)$-713.94

10-Day Avg Trading Volume0.26M

EPS Excl Extra (TTM)$-713.94

Revenue Growth (5Y)4.17%

EPS (Annual)$-801.83

ROI (Annual)-84.95%

Gross Margin (Annual)67.21%

Net Profit Margin (5Y Avg)-565.36%

Cash / Share (Quarterly)$19.57

Revenue Growth QoQ (YoY)815.63%

ROA (Last FY)-139.43%

Revenue Growth TTM (YoY)155.96%

EBITD / Share (TTM)$-145.11

ROE (5Y Avg)-412.67%

Operating Margin (TTM)-97.17%

Cash Flow / Share (Annual)$-119.03

P/B Ratio0.66x

P/B Ratio (Quarterly)1.46x

Net Income / Employee (Annual)$-1,136,900

EV / Revenue (TTM)1.00x

Net Interest Coverage (TTM)-7.53x

ROA (TTM)-78.67%

EPS Incl Extra (Annual)$-801.83

Current Ratio (Annual)0.50x

Quick Ratio (Quarterly)0.25x

3-Month Avg Trading Volume0.12M

52-Week Price Return-98.55%

Revenue / Employee (TTM)$629,100

Tangible BV / Share (Quarterly)$3.89

P/S Ratio (Annual)0.32x

Asset Turnover (Annual)0.30x

52-Week High$85.40

Operating Margin (5Y Avg)-448.71%

EPS Excl Extra (Annual)$-801.83

CapEx CAGR (5Y)42.41%

26-Week Price Return-95.80%

Quick Ratio (Annual)0.23x

13-Week Price Return-73.72%

Total Debt / Equity (Annual)3.64x

Current Ratio (Quarterly)0.50x

Enterprise Value$29.57M

Revenue / Share Growth (5Y)-43.97%

Asset Turnover (TTM)0.68x

Book Value / Share Growth (5Y)751.93%

Revenue / Employee (Annual)$244,900

Inventory Turnover (Annual)0.40x

Pretax Margin (Annual)-469.09%

Cash / Share (Annual)$4.86

3-Month Return Std Dev123.97%

Gross Margin (5Y Avg)71.78%

Net Income / Employee (TTM)$-726,000

ROE (Last FY)-393.98%

Net Interest Coverage (Annual)-4.70x

EPS Basic Excl Extra (Annual)$-801.83

Receivables Turnover (TTM)45.81x

Total Debt / Equity (Quarterly)5.47x

EPS Incl Extra (TTM)$-713.94

Receivables Turnover (Annual)7.55x

ROI (TTM)-100.53%

P/S Ratio (TTM)0.13x

Pretax Margin (5Y Avg)-570.46%

Revenue / Share (Annual)$172.73

Tangible BV / Share (Annual)$-5.37

Price vs S&P 500 (52W)-116.86%

Year-to-Date Return-97.20%

5-Day Price Return-6.61%

EPS Normalized (Annual)$-801.83

ROA (5Y Avg)-98.32%

Net Profit Margin (Annual)-464.20%

Month-to-Date Return-8.80%

Cash Flow / Share (TTM)$-3.41

EBITD / Share (Annual)$-687.18

Operating Margin (Annual)-414.45%

LT Debt / Equity (Annual)2.41x

ROI (5Y Avg)-111.61%

LT Debt / Equity (Quarterly)1.36x

EPS Basic Excl Extra (TTM)$-713.94

P/TBV (Quarterly)26.17x

P/B Ratio (Annual)1.22x

Inventory Turnover (TTM)0.48x

Pretax Margin (TTM)-117.28%

Book Value / Share (Annual)$16016.48

Price vs S&P 500 (13W)-76.51%

Beta-0.17x

Revenue / Share (TTM)$57.33

ROE (TTM)-582.86%

52-Week Low$0.72

vGradeA

gGradeB

mGradeF

vgmGradeC

JAGX Earnings Surprise History

Q1 25-584.50est. -378.70

Q2 25-259.26est. -249.55

Q3 25-219.80est. -177.80

JAGX Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.29

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
JAGXJaguar Health, Inc.	A	B	F	$0.92
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Jaguar Health, Inc.

Jaguar Health is a commercial-stage biopharmaceutical company developing plant-based, non-opioid prescription medicines for gastrointestinal disorders, primarily chronic diarrhea. Its lead product, Mytesi, is a first-in-class anti-secretory agent with potential applications across multiple GI indications in both human and animal health markets. The company generates revenue primarily from its human health segment.